High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission.
Arnav AgarwalJohn BasmajiFiona MuttalibDavid GrantonDipayan ChaudhuriDevin ChetanMalini HuShannon M FernandoKimia HonarmandLayla BakaaSonia BrarBram RochwergNeill K AdhikariFrancois LamontagneSrinivas MurthyDavid S C HuiCharles GomersallSamira MubarekaJanet V DiazKaren E A BurnsRachel CoubanQuazi IbrahimGordon H GuyattPer Olav VandvikPublished in: Canadian journal of anaesthesia = Journal canadien d'anesthesie (2020)
High-flow nasal cannula may reduce the need for invasive ventilation and escalation of therapy compared with COT in COVID-19 patients with acute hypoxemic respiratory failure. This benefit must be balanced against the unknown risk of airborne transmission.
Keyphrases
- respiratory failure
- extracorporeal membrane oxygenation
- systematic review
- mechanical ventilation
- coronavirus disease
- chronic rhinosinusitis
- sars cov
- randomized controlled trial
- particulate matter
- acute respiratory distress syndrome
- open label
- human health
- meta analyses
- stem cells
- risk assessment
- clinical trial
- study protocol
- obstructive sleep apnea
- air pollution